Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clobetasol propionate + retapamulin is a topical combination drug consisting of two active ingredients with complementary mechanisms for the treatment of skin conditions. Clobetasol propionate is a potent synthetic corticosteroid that acts as an anti-inflammatory and immunosuppressive agent by binding to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory gene expression. It reduces swelling, redness, itching, and rashes associated with various dermatoses[2][7][8][9]. Retapamulin is a semisynthetic pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis at the level of the 50S ribosomal subunit, making it effective against certain Gram-positive bacteria such as Staphylococcus aureus (methicillin-susceptible) and Streptococcus pyogenes[1][4][6][10]. The combination may be used for inflammatory skin conditions complicated by or at risk for secondary bacterial infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobetasol propionate + retapamulin.